NASC (Nascent Pharma Holdings) Selling, General, & Admin. Expense: $4.12 Mil (TTM As of Sep. 2024)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Selling, General, & Admin. Expense?

Nascent Pharma Holdings NASC -0.03% 12 Selling, General, & Admin. Expense is $4.12 Mil as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Nascent Pharma Holdings's selling, general, & admin. expense for the three months ended in Sep. 2024 was $2.43 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2024 was $4.12 Mil.


Nascent Pharma Holdings  (OTCPK:NASC) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Nascent Pharma Holdings Selling, General, & Admin. Expense Related Terms


Nascent Pharma Holdings Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Selling, General, & Admin. Expense Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.45 5.13 9.64 12.62 4.75

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 -1.17 1.69 1.17 2.43

NASC vs ALID, CPMD, PLSH: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Pharma Holdings Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's Selling, General, & Admin. Expense falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $4.12 Mil mean?
Nascent Pharma Holdings (NASC) has a Selling, General, & Admin. Expense of $4.12 Mil as of Sep. 2024. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Selling, General, & Admin. Expense too high?
Nascent Pharma Holdings' current Selling, General, & Admin. Expense is $4.12 Mil. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Selling, General, & Admin. Expense compare to ALID and CPMD?
Nascent Pharma Holdings' Selling, General, & Admin. Expense of $4.12 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Selling, General, & Admin. Expense is $4.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Selling, General, & Admin. Expense of $4.12 Mil. The current Selling, General, & Admin. Expense is $4.12 Mil. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Selling, General, & Admin. Expense is $4.12 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price